Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net income	$ 10,581,000	$ 2,373,000
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	373,000	245,000
Loss on disposal of property and equipment	13,000
Stock-based compensation expense	1,907,000	1,131,000
Amortization of deferred rent related to lease incentives	0	(95,000)
Amortization of operating lease liability	(132,000)
Interest expense – finance type lease	2,000
Loss from equity method investment in SAVSU	739,000	363,000
Gain on acquisition of SAVSU	(10,108,000)
Amortization of intangible assets	465,000
Change in operating assets and liabilities
Accounts receivable, trade	(372,000)	(1,678,000)
Inventories	(1,730,000)	(1,064,000)
Prepaid expenses and other current assets	(272,000)	(49,000)
Other assets, net	(87,000)
Accounts payable	377,000	343,000
Accrued compensation and other current liabilities	558,000	205,000
Other liabilities	(98,000)	(11,000)
Net cash provided by operating activities	2,216,000	1,763,000
Cash flows from investing activities
Investment in iVexSol	(1,000,000)
Investment in SAVSU		(6,000,000)
Purchase of property and equipment	(356,000)	(339,000)
Purchase of Assets Held for Rent	(453,000)
Net cash used in investing activities	(12,997,000)	(6,339,000)
Cash flows from financing activities
Proceeds from private equity transaction		20,000,000
Payment of costs related to Stock Issuances	(44,000)	(43,000)
Payments on equipment loan	(12,000)	(8,000)
Payments on finance lease obligations	(9,000)	(10,000)
Proceeds from exercise of common stock options and warrants	1,394,000	11,724,000
Payments of preferred stock dividends		(306,000)
Payments for redemption of preferred stock		(1,063,000)
Net cash provided by financing activities	1,329,000	30,294,000
Net increase (decrease) in cash and cash equivalents	(9,452,000)	25,718,000
Cash and cash equivalents - beginning of period	30,657,000	6,663,000
Cash and cash equivalents - end of period	21,205,000	32,381,000
Non-cash investing and financing activities
Series A preferred stock dividends accrued not yet paid		80,000
Stock issued for services provided in prior period included in liabilities at year-end		36,000
Receivables converted to equity investment in SAVSU		150,000
Purchase of equipment with debt		18,000
Purchase of property and equipment not yet paid	146,000	49,000
Financing costs not yet paid	53,000
Stock Issued as consideration to acquire SAVSU	19,932,000
SAVSU [Member]
Adjustments to reconcile net income to net cash provided by operating activities
Gain on acquisition of SAVSU	(10,100,000)
Cash flows from investing activities
Cash acquired on acquisition of SAVSU	1,251,000
Astero [Member]
Cash flows from investing activities
Payments related to the Astero Bio Acquisition, net of cash acquired	$ (12,439,000)